On February 20, 2020, VistaGen Therapeutics, Inc. (the “Company”) announced positive results from a newly published exploratory Phase 2a clinical study of PH10, the Company’s investigational first-in-class, rapid-onset synthetic neurosteroid nasal spray, for treatment of major depressive disorder. Results of the double-blind, randomized, placebo-controlled Phase 2a study have been published in the peer-reviewedBritish Journal of Pharmaceutical and Medical Research. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01. Exhibits.

(d) Exhibits

VistaGen Therapeutics, Inc. Exhibit
EX-99 2 ex99-1.htm PRESS RELEASE Blueprint   Exhibit 99.1     VistaGen Announces Positive Results of Newly Published Exploratory Phase 2a Study of PH10 for Rapid-Onset Treatment of Major Depressive Disorder   PH10,…
To view the full exhibit click here

About VistaGen Therapeutics, Inc. (NASDAQ:VTGN)

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system (CNS). Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder (MDD) in patients with an inadequate response to standard antidepressants approved by the United States Food and Drug Administration (FDA). In addition to AV-101, the Company has developed a human pluripotent stem cell (hPSC) technology platform, which includes its in-vitro bioassay system, CardioSafe 3D, to predict potential heart toxicity of new chemical entities (NCEs) long before testing in animal and human studies. The Company is focused on regenerative medicine (RM) applications using blood, cartilage, heart and/or liver cells derived from hPSCs.